G-CSF trial on SAA patients treated with ATG and CSA with or without G-CSF
Data Quality Initiative of the SAAWP
Join the CMML Data Quality Initiative
Transformed Fanconi Anaemia
CTIWP survey to identify current policies to monitor post-transplant immune reconstitution
We are trying to contact all centres who participated in this trial to request an update of the patient status. Did you (or your centre) participate in this trial and you did not receive an invitation to provide follow-up on your patients? Please send your email to firstname.lastname@example.org.
If you have questions, please contact Cora Knol or Paul Bosman of the EBMT Data Office via email@example.com.
This Data Quality Initiative (DQI) aims to include more patients with complete data regarding pre-treatment, cytogenetics, comorbidities, GvHD prophylaxis, as well as follow up information. All future CMML studies would benefit from this DQI.
To participate with the CMML DQI, please fill in the excel file you received from us in August/September 2017 or contact us by sending an email to firstname.lastname@example.org
A study by the SAAWP and CMWPThe Severe Aplastic Anaemia Working Party wants to assess the outcome of patients affected by Fanconi Anaemia with MDS or acute leukaemia (Fanconi transforming to MDS or acute leukaemia) or cytogenetic abnormalities in terms of overall survival and disease free survival. The role of pre-transplant cytoreductive treatment and what is the most advisable approach in FA patients with MDS/AML remain unclear, since published studies on this topic include small numbers of highly heterogeneous patients with a variety of different therapies performed. While the largest studies on FA have lacking information on pre-transplant approaches.
Inclusion criteria for this study are:
Data collection will include a.o. diagnostic features, previous cytoreductive protocols, donor characteristics and outcome measures. We would like to ask you to participate in this study and share data on patients with transformed Fanconi Anaemia in your centre. Please indicate via the online survey that is available whether you have eligible patients and are willing to participate in this study: https://www.surveymonkey.com/r/transformedFA. We would be very grateful if you could fill out the survey before December 1st, 2017.
For more information or to request the Restricted MED-B/C form, please contact Cora Knol/Paul Bosman via email@example.com.
A survey by the CTIWP* This survey is still open *
The EBMT Cellular Therapy & Immunobiology Working Party (CTIWP) is conducting a survey to identify current policies to monitor immune reconstitution in patients undergoing allo-HSCT. To this end a questionnaire has been designed to cover the most used quantitative and qualitative features of immune recovery after HSCT.
We would appreciate if you could participate in this survey, to help us designing a proper retrospective study concerning the monitoring of post-transplant immune reconstitution.